A 53-year-old man presented with focal jacksonian seizures that were due to cerebral tumour manifestations. Stereotactic biopsy revealed infiltration by lymphocytes compatible with the diagnosis of chronic lymphocytic leukaemia (CLL). Simultaneously, Binet stage II CLL with bone marrow infiltration was diagnosed. Cranial radiotherapy with 36 Gy was performed. One year after diagnosis, the patient is in stable disease. Cerebral involvement is rare but may occur in early CLL. Cranial radiotherapy may lead to lasting remission. In case of spinal fluid involvement intrathecal chemotherapy is recommended.

Anonymous: A clinical evaluation of the International Lymphoma Study group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:3909–3918.
O’Neill BP, Habermann TM, Banks P, O’Fallon JR, Earle JD: Primary central nervous system lymphomas as a variant of Richter’s syndrome in two patients with chronic lymphocytic leukemia. Cancer 1989;64:1296–1300.
Cramer SC, Glaspy JA, Efrid JT, Louis DN: Chronic lymphocytic leukaemia and the central nervous system: A clinical and pathological study. Neurology 1996;46:19–25.
Marmont AM: Leukemic meningitis in B-cell chronic lymphocytic leukemia: Resolution following intrathecal methotrexate. Blood 2000;96:776–777.
Majumdar G: Chronic lymphocytic leukemia with cerebral infiltration. Leuk Lymphoma 1998;28:603–605.
Pohar S, de Metz C, Poppema S, Hugh J: Chronic lymphocytic leukemia with CNS involvement. J Neurooncol 1993;16:35–37.
Elliott MA, Letendre L, Li C-Y, Hoyer J, Hammack JE: Chronic lymphocytic leukemia with symptomatic diffuse central nervous system infiltrating responding to therapy with systemic fludarabine. Br J Haematol 1999;104:689–694.
Cid J, Revilla M, Cervera A, Cervantes F, Munoz F, Ferrer I, Montserrat E: Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol 2000;79:392–395.
Quitt M, Bazac I, Gross B, Aghai E: Fulminant bilateral cerebellar syndrome in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 1994;15:507–510.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.